TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02237144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash transfer
Description: 1500 taka ($18.75) per household distributed monthly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash transfer
Description: 1500 taka ($18.75) per household distributed monthly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food transfer
Description: 30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food transfer
Description: 30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food and cash transfer
Description: 15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Communication Change (BCC)
Description: Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Communication Change (BCC)
Description: Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
Study: NCT04075955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zyprexa® (OLANZapine 5MG)
Description: Olanzapine 5mg orally at bedtime for 4 days (starting the day before the chemotherapy)~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally twice a day for 6 doses (starting on the morning of day 2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emend® (Aprepitant)
Description: Aprepitant 125mg orally pre-chemotherapy on day 1, then 80mg orally once daily on days 2 and 3~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally once daily for 3 doses (starting on the morning of day 2)
Study: NCT02079311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active self warming blanket
Description: BARRIER® EasyWarm is a disposable self-warming blanket that produces heat via an exothermic chemical reaction initiated by exposure to air, resulting from the oxidation of iron.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forced air warming device
Description: Forced air warming is a temperature management unit, where heated air is used to warm subjects through convection.
Study: NCT01970540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurbinectedin (PM01183)
Description: lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Commercially available presentations of vials containing doxorubicin will be provided as appropriate.
Study: NCT01142778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: All participants will undergo surgery (as per investigator's discretion) after Cycle 7 and between 4 and 6 weeks after the study treatment infusion in Cycle 6 (1 Cycle=21 days).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: All participants will receive radiotherapy starting about 4 to 8 weeks after surgery, and will last around 4 to 6 weeks as per site's standard practice.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: All participants will receive radiotherapy starting about 4 to 8 weeks after surgery, and will last around 4 to 6 weeks as per site's standard practice.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All participants will receive radiotherapy starting about 4 to 8 weeks after surgery, and will last around 4 to 6 weeks as per site's standard practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormonal Therapy
Description: Participants who are hormone receptors positive, will receive hormonal therapy after completion of radio therapy period as per investigator's discretion and site's standard practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormonal Therapy
Description: Participants who are hormone receptors positive, will receive hormonal therapy after completion of radio therapy period as per investigator's discretion and site's standard practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormonal Therapy
Description: Participants who are hormone receptors positive, will receive hormonal therapy after completion of radio therapy period as per investigator's discretion and site's standard practice.
Study: NCT01016717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: All patients will be taking omeprazole (Losec, Abic Inc., Israel) tablets 40 mg QD for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Pantoprazole tablets (Controloc 40, 40 mg/day, Nycomed, Perrigo Inc., Israel). All patients will take pantoprazole tablets 40 mg QD for 30 days
Study: NCT00737217

Intervention type: BEHAVIORAL
Intervention: Behavioral assessment/questionnaire
Description: Complete behavioral assessment/questionnaire

Intervention type: BEHAVIORAL
Intervention: Behavioral assessment/questionnaire
Description: Complete behavioral assessment/questionnaire
Study: NCT03476798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15mg/kg IV on day 1 of each cycle
Study: NCT02054091

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Description: The BC powder to be used in this study is donated from a Danish company, Biofiber Damino. The raw colostrum used for production is collected within 1-2 milking from healthy Danish dairy cows (Danish Holstein). Antibiotic residues are screened upon collection and those tested positive are not used for production. Intact colostrum is pasteurized, low temperature spray-dried, and sterilized by γ-irradiation.
Study: NCT02026739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low supplemental oxygen concentration
Description: low supplemental oxygen concentration would be used during the surgery
Study: NCT03737409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulatory Oxygen Therapy
Description: Supplemental oxygen delivered during exercise and activities of daily living via a portable oxygen concentrator

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Ambulatory Oxygen Therapy
Description: Air delivered during exercise and activities of daily living via a portable oxygen concentrator that has been modified to deliver air
Study: NCT00101920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-EGF
Description: 2.5 mg/kg by an infusion pump over one hour
Study: NCT05366621

Intervention type: DRUG
Intervention: Anti-osteoporosis medications
Description: Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).

Intervention type: DRUG
Intervention: Anti-osteoporosis medications
Description: Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).
Study: NCT01907308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
Study: NCT01825148

Intervention type: OTHER
Intervention: radiolabeled Exendin

Intervention type: OTHER
Intervention: radiolabeled Exendin
Study: NCT00089024

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: A re-staging CT scan, which will be obtained as part of the radiation simulation, will be used to assess any possible response to the initial two cycles of chemotherapy. Unless the patient has developed evidence of metastatic disease, chemoradiation will proceed. Patients who required no treatment delays will commence chemoradiation on day 42. If a one-week delay is needed before cycle 2 of neo-adjuvant chemotherapy can be delivered, the patient will begin chemoradiation on day 49 provided treatment-related toxicity has resolved. If cycle 2 could not be given (2 or more week delay for resolution of treatment-related toxicity), then chemoradiation will begin once toxicity has resolved (may be earlier than day 42).
Study: NCT01987479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-Biologic DMARDs
Description: Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered per investigator's discretion.
Study: NCT00143923

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition, Exercise, Stress Management Counseling
Description: Individualized advice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: usual care
Study: NCT02409680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose aspirin
Description: Daily administration of low dose (81 mg) aspirin \[also known as acetylsalicylic acid (ASA\], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly.
Study: NCT01138293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: motion detection with a motion sensor
Description: To asses physical activity and eating habits electronic health technology was used (Fraunhofer-Institute). The system consists in a motion sensor integrated in a mobile phone (DiaTrace). The system analyses kind, intensity and duration of physical activity and eating habits.
Study: NCT03223740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1 pre-operative chemoradiation
Description: Chemotherapy 1:~First 2 courses of chemotherapy with the Capacitabine /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a one-hour bolus on day1-5.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~Four to five weeks after chemoradiotherapy, Restaged and surgical resection, a D2 resection is encouraged. Peritoneal cytology will be obtained. The J-tube will be left in for at least 8 weeks after surgery to supplement patient's nutrition.~2nd courses of chemotherapy with the Capacitabine. Capacitabine1 g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 post operative chemoradiation
Description: Surgical resection, a D2 resection is encouraged.~Chemotherapy 1:~All patients will first receive two courses of chemotherapy with the Capacitabin /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a bolus on day1-5. Chemotherapywill be repeated beginning on Day 22.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~2nd courses of chemotherapy with the Capacitabin. Capacitabine 1g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29
Study: NCT02409680

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06067763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Health
Description: A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Health
Description: A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response and Attention Training
Description: Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response and Attention Training
Description: Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Weight of the Nation
Description: This 2012 documentary discusses the facts and myths about obesity and the impacts of obesity on individuals and the health care system in the United States.
Study: NCT04330456

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative stereotactic radiation therapy in hypofractionation mode
Description: At the first step patient undergoes preoperative stereotactic radiation therapy in hypofractionation mode. Radiation therapy plan is based on topometric MRI and CT scans. Radiation therapy plan are performed after MRI and CT fusion, contouring of the target and surrounding normal tissues.~At first step only tumor and, if necessary, the surrounding normal tissues, which will be removed during surgery, are exposed to radiation.~GTV - determined in with the boundaries of the tumor visualised by topometric MRI and CT CTV1 - match GTV CTV2 - formed inward (to the tumor center) from GTV by 0.5-1 cm (depending on the proximity of functionally significant normal tissues (neurovascular bundles, bone tissue, skin and subcutaneous fat, etc.) PTV - 3-5 mm indent from CTV1, taking into account the proximity of functionally significant normal tissues and the planned surgery Preoperative radiation therapy is carried in 5 fractions with a single dose on PTV - 5 Gy, a single dose on CTV2 - 7 Gy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: In 14-21 days after preoperative stereotactic radiation therapy radical surgery will be performed
Study: NCT02647827

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle management
Description: All women will receive lifestyle management instructions at the baseline visit, before randomization. The lifestyle management involves one initial counselling session in connection with the baseline visit, which includes information about the importance of weight management, healthy diet and physical activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle management
Description: All women will receive lifestyle management instructions at the baseline visit, before randomization. The lifestyle management involves one initial counselling session in connection with the baseline visit, which includes information about the importance of weight management, healthy diet and physical activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle management
Description: All women will receive lifestyle management instructions at the baseline visit, before randomization. The lifestyle management involves one initial counselling session in connection with the baseline visit, which includes information about the importance of weight management, healthy diet and physical activity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Disposable, single-use, sterilized CE marked needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50 mm will be inserted to a depth of 15-40 mm in segmental acupuncture points located in abdominal and leg muscles, with innervations corresponding to the ovaries and the pancreas. Two sets of acupuncture points will be alternated every second treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral metformin 500 mg three times daily, in total 1500 mg per day. To reduce gastrointestinal side-effects of metformin, the dose will be slowly escalated starting with 500 mg daily during the first week, increasing to 500 mg twice per day during the second the week, and 500 mg three times daily, morning, lunch and dinner from the third week in total 16 weeks including the 3 weeks step-up phase (i.e. 4 months).
Study: NCT04129229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LinguaFlex Tongue Retractor (LTR)
Description: The LinguaFlex Tongue Retractor (LTR) is a small, flexible, implanted tongue retaining device that lessens the backward movement of the tongue during sleep. The LTR's flexible shaft and a nubbed tether passes through the center of the tongue beneath the tongue blade (frenulum area) and connects to a disc (head) that rests on the external surface of the tongue base mucosa. Underneath the tongue, on the external surface of the frenulum, a small anchor secures the shaft that can be adjusted to tension the LTR to maximize therapeutic effect and maintain comfort.
Study: NCT06697132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic dismembered pyeloplasty
Description: Modified antegrade stenting in laparoscopic pediatric pyeloplasty
Study: NCT04330456

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postoperative conformal radiation therapy in normofractionation mode
Description: In 25-35 days after the surgery postoperative conformal radiation therapy is performed according to the standard protocol GTV (tumor bed) - based on the volume of the primary tumor, including the swelling zone (T2-weighted images on preoperative MRI) СTV - formed with an indent of 4 cm from GTV (without going beyond the boundaries of the involved compartment), in the transverse direction the indent could be reduced to 2 cm.~PTV - formed with an indent of 0.5-1cm from CTV An important condition for planning radiation therapy is to limit the dose absorbed during both stages of radiation therapy in surrounding normal tissues that are not removed during surgery.
Study: NCT02202161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
Study: NCT03295981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: 4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement
Study: NCT03363386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proprioceptive Exercises
Description: Patients trained for proprioceptive exercises

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resistive Exercises
Description: Patients trained for resistive exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Patients were educated with treadmill walking for 30 minutes of each exercise session

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Patients were educated with treadmill walking for 30 minutes of each exercise session
Study: NCT04277143

Intervention type: DRUG
Intervention: Daptomycin
Description: Adult patients are given the recommended dose of daptomycin for injection. Patients with creatinine clearance (CLCR) ≥ 30 mL / min: 6 mg / kg every 24 hours.~Patients with creatinine clearance (CLCR) \<30mL / min (including hemodialysis or peritoneal dialysis): 6mg / kg every 48 hours. Dissolve 6mg / kg of this drug in 0.9% sodium chloride injection and instill it over a 30-minute time course once every 24 or 48 hours.
Study: NCT01860677

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fisher Wallace Cranial Stimulator
Description: The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies.
Study: NCT02415049

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incremental Feeds
Description: This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad lib feeds
Description: This arm of patients will be fed ad lib following pyloromyotomy. They will be allowed to eat as frequently as they desire based on infant cues to a goal of 12.5ml/kg/feed
Study: NCT00120081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-ASP-2/Alhydrogel Hookworm Vaccine
Description: The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-ASP-2/Alhydrogel Hookworm Vaccine
Description: The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-ASP-2/Alhydrogel Hookworm Vaccine
Description: The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Inactive saline placebo control
Study: NCT02660593

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SanGrow Decoction
Description: SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.